NCT03255629View on ClinicalTrials.gov

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

August 22, 2018

Study Completion Date

August 22, 2018

Conditions
Post-bariatric Hypoglycemia
Interventions
DRUG

glucagon

novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals

DEVICE

Closed loop glucagon pump

a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.

Trial Locations (1)

02215

Joslin Diabetes Center, Boston

Sponsors

Collaborators (1)

Xeris Pharmaceuticals
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Xeris Pharmaceuticals

INDUSTRY

collaborator

Harvard University

OTHER

lead

Joslin Diabetes Center

OTHER